ARTICLE | Clinical News
VLTS Phase IIb IL-2 data
December 3, 2001 8:00 AM UTC
Valentis (VLTS) said the final analysis of an 80-patient European Phase IIb trial of its IL-2 GeneMedicine gene therapy to treat head and neck cancer failed to confirm previously reported interim resu...